Skip to main content
Premium Trial:

Request an Annual Quote

SBI and GeneFormatics Become Cengent Therapeutics

This article has been updated to clarify a financial term.


NEW YORK, May 19 - The merger between Structural Bioinformatics and GeneFormatics has been finalized and the new company is named Cengent Therapeutics, the company said today.


The merger, announced January 6, has been approved by the California Department of Corporations as well as the shareholders of both companies, the company said.


The name Cengent was chosen because it reflects "a combination of science and engineering, as well as the concept of intelligence," according to CEO Edward Maggio.  In this case, "combination" is perhaps the operative word. The company has added SBI's X-ray crystallography and databases to GeneFormatics' expertise in NMR-based structure analysis, databases, and informatics. And, in addition to combining their roster of pharmaceutical and biotech collaborators, they have pooled their resources to jump further into pre-clinical drug discovery programs.


Cengent has a number of pre-clinical drug development programs in obesity/diabetes, anti-infectives, oncology, and inflammation. The diabetes/obesity drug is the furthest along, according to Maggio, who said that there has been interest from potential pharma and biotech partners.


In the financial arena, the combination also strengthens the company. Cengent has raised over $90 million to date, and has enough money to last beyond 2005, according to management.


The company will be headquartered at SBI's San Diego facilities, and by September, all GeneFormatics' employees - along with technologies such as the NMR spectroscopes - will be moved to this facility, Maggio said.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.